Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could ease stiffness and pain for ankylosing spondylitis patients

NCT ID NCT07172360

Disease control Sponsor: Jiangsu vcare pharmaceutical technology co., LTD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether VC005 tablets can reduce symptoms of active ankylosing spondylitis, a type of arthritis that mainly affects the spine. About 420 adults aged 18 to 70 will receive either VC005 or a placebo for 48 weeks. The main goal is to see how many achieve a 20% improvement in disease activity after 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VC005 tablets
What this could lead to
If successful, this could provide a new oral treatment option to control symptoms and slow disease progression in people with active ankylosing spondylitis.
What could go wrong
This is still an experimental drug. Phase 3 trials can fail to show enough benefit or reveal unexpected side effects. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 420 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol; * The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender; * The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis Exclusion Criteria: * Those who may be allergic to VC005, similar drugs or their excipients. * Individuals who have undergone organ transplantation in the past and require continuous use of immunosuppressants. * Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Active ankylosing spondylitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Active ankylosing spondylitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University People's Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.